Stanford University's Department of Anesthesiology, Perioperative and Pain Medicine has launched what researchers say is the first rigorously controlled clinical trial in the Bay Area to examine how specific formulations of cannabis affect chronic pain in adult patients who have not responded to conventional treatments.
The trial, funded by a $4.1 million grant from the National Institutes of Health and a matching contribution from the California Initiative to Advance Precision Medicine, will recruit 400 participants from three San Jose-area pain management clinics over the next six months. Enrollment is open now.
"We have millions of Californians using cannabis for pain relief, and almost no rigorous data guiding them. This trial is designed to change that — and to give physicians something they can actually use." — Dr. Linda Patel, Principal Investigator, Stanford Pain Management Center
The study will test four different cannabinoid formulations — ranging from high-THC to high-CBD and balanced blends — against a placebo across a 24-week treatment period. Participants will be randomly assigned to one of the five arms and assessed monthly using validated pain-scoring instruments, functional mobility assessments, and sleep quality indices.
Who Can Participate
To qualify, participants must be adults aged 25 to 75 living in Santa Clara County who have been diagnosed with one of four qualifying chronic pain conditions: fibromyalgia, failed back surgery syndrome, complex regional pain syndrome, or diabetic neuropathy. Applicants must have tried at least two conventional treatments — such as opioids, NSAIDs, or nerve block therapy — without adequate relief.
Participants with a history of cannabis use disorder, active psychosis, or pregnancy are not eligible. Those who currently use cannabis for pain are eligible to apply but must complete a two-week washout period before the study begins.
Compensation is provided: participants will receive $50 per completed monthly visit, with a $200 bonus for completing all six assessments. All cannabis products and placebo materials are provided at no cost. Transportation reimbursement is available for participants traveling more than 10 miles to a clinic site.
Why San Jose?
The choice to anchor the trial in San Jose is deliberate, researchers said. Santa Clara County's population is among the most racially and ethnically diverse in California, and prior cannabis research has been criticized for over-representing white, college-educated participants. The trial has a specific recruitment target of 40 percent Latino participants, 20 percent Asian American, and 15 percent Black — reflecting the demographics of the county's chronic pain patient population.
"If we only study pain relief in one demographic, we only get answers for one demographic. San Jose gives us the diversity we need to produce findings that are actually generalizable." — Dr. Yolanda Reyes, Co-Investigator and UCSF Clinical Liaison
Local dispensaries, including Purple Lotus and Harborside, have agreed to serve as community information partners — making intake forms available in-store and training budtenders to refer interested customers to the study screening hotline. The partnership is informational only; the dispensaries have no financial stake in the trial and will not supply any products used in the study.
How to Apply
Interested residents can call the Stanford Pain Research Line at (650) 724-PAIN or visit the trial's enrollment page at med.stanford.edu/painresearch. Walk-in screening sessions will be held every Saturday from 9 a.m. to noon at the Eastridge Health Clinic, 2200 Eastridge Loop, San Jose, beginning March 8.